Bryan Brooks, MD
Ophthalmology · Glen Allen, VANPI 1972530673
Payments from drug & device makers
Across 145 payments — averaging $38.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$3K
- Notal Vision, Inc.$446
- Sun Pharmaceutical Industries Inc.$340
- Bausch & Lomb, A Division Of Bausch Health US, LLC$271
- Mallinckrodt Hospital Products Inc.$230
- Ocular Therapeutix, Inc.$150
- plus $1K from 16 others
What the payments were for
- Consulting fees$2,13238%
- Speaking & faculty fees$3767%
- Food & beverage$2,95953%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 45 | $2,948 |
| Notal Vision, Inc. | 4 | $446 |
| Sun Pharmaceutical Industries Inc. | 18 | $340 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 14 | $271 |
| Mallinckrodt Hospital Products Inc. | 6 | $230 |
| Ocular Therapeutix, Inc. | 2 | $150 |
| NEW World Medical,inc. | 1 | $150 |
| AbbVie(2 entities) | 8 | $135 |
| Bausch & Lomb Americas Inc. | 6 | $117 |
| Oyster Point Pharma, Inc. | 5 | $113 |
| Biotissue Holdings Inc. | 6 | $104 |
| Novartis | 4 | $91 |
| Mallinckrodt Enterprises LLC | 3 | $70 |
| Alcon | 4 | $67 |
| Harrow Eye, LLC | 3 | $61 |
| Kala Pharmaceuticals, Inc. | 4 | $57 |
| Aerie Pharmaceuticals, Inc. | 3 | $51 |
| Omeros Corporation | 3 | $50 |
| Sight Sciences, Inc. | 2 | $42 |
| Eyevance Pharmaceuticals LLC | 2 | $36 |
| Amgen | 1 | $24 |
| Eyepoint US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,567 in reported general payments places this provider in the 80th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 145 | $76,435 |
| RestasisCyclosporine | 38 | $51,245 |
| RocklatanNetarsudil Mesylat/Latanoprost | 26 | $14,074 |
| CombiganBrimonidine Tartrate/Timolol | 23 | $11,678 |
| Prednisolone Acetate | 228 | $9,596 |
| VyzultaLatanoprostene Bunod | 23 | $9,120 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 34 | $8,327 |
| Travoprost | 46 | $6,161 |
| Cyclosporine | 11 | $5,956 |
| Latanoprost | 615 | $5,408 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 192 | $4,071 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 21 | $3,416 |
| TafluprostTafluprost/Pf | 24 | $3,374 |
| Bromfenac Sodium | 17 | $3,322 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 21 | $3,134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $135 | $139,357206 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $51 | $14,07426 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $117 | $9,12023 claims |
| AlconSimbrinza | $67 | $8,32734 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $271 | $2,75117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Glen Allen
- James PaauwLynchburg$7M
- Golnaz JaveyLynchburg$6.7M
- Kapil KapoorNorfolk$4.3M
- Ali TabassianRichmond$2.1M
- Elizabeth Yeu-LinNorfolk$2M
- Ethnie JonesRichmond$2M
- Alan WagnerNorfolk$1.8M
- John SheppardNorfolk$1.2M
- Gustavo CorralesFalls Church$888K
- Frank CotterRoanoke$874K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.